Advanced Science · 2024 · 10 citations · 59 references
Life SciencesImmunologyOncologyImmunotherapyTumor ImmunologyTumor MicroenvironmentCancer ImmunotherapyCancer TranscriptomicsCheckpoint Inhibitor TherapyImmune Checkpoint RegulationInterferon ResponsesTumor Microenvironment ModulationAntitumor Interferon ResponsesCd8 T Cell ActivationCellular ImmunotherapyEnrichment AnalysisImmunosuppressive MicroenvironmentInhibition Of Interferon ResponsesInnate Antitumor ImmunityInterferon Production
The success of immunotherapy for cancer treatment is limited by the presence of an immunosuppressive tumor microenvironment (TME); Therefore, identifying novel targets to that can reverse this immunosuppressive TME and enhance immunotherapy efficacy is essential. In this study, enrichment analysis based on publicly available single-cell and bulk RNA sequencing data from gastric cancer patients are conducted, and found that tumor-intrinsic interferon (IFN) plays a central role in TME regulation. The results shows that KDM3A over-expression suppresses the tumor-intrinsic IFN response and inhibits KDM3A, either genomically or pharmacologically, which effectively promotes IFN responses by activating endogenous retroviruses (ERVs). KDM3A ablation reconfigures the dsRNA-MAVS-IFN axis by modulating H3K4me2, enhancing the infiltration and function of CD8 T cells, and simultaneously reducing the presence of regulatory T cells, resulting in a reshaped TME in vivo. In addition, combining anti-PD1 therapy with KDM3A inhibition effectively inhibited tumor growth. In conclusions, this study highlights KDM3A as a potential target for TME remodeling and the enhancement of antitumor immunity in gastric cancer through the regulation of the ERV-MAVS-IFN axis.
59
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le, Jennifer N. Uram, Hao Wang et al. · New England Journal of Medicine · 2015 · 9.4K citations · Full text
Life Sciences, Immunology, Oncology +17
Yung‐Jue Bang, Eric Van Cutsem, A. Feyereislova et al. · The Lancet · 2010 · 7.3K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Yelena Y. Janjigian, Kohei Shitara, Markus Moehler et al. · The Lancet · 2021 · 2.9K citations · Full text
Medicine, Oncology, Pharmacotherapy +16